The current paradigm for anticoagulation in patients with atrial fibrillation is based upon clinical risk factors for stroke without reference to the frequency or duration (i.e., burden) of atrial fibrillation episodes. In the last decade, increasing evidence derived from device-based surveillance of atrial fibrillation has suggested that in some patients the burden of atrial fibrillation may be associated with thromboembolic risk. The development of rapidly acting oral anticoagulants and devices with remote monitoring capability has allowed the testing of a strategy of tailored or "pill-in-the-pocket" anticoagulation based upon atrial fibrillation burden.
Keywords: atrial fibrillation; clinical trials; electrophysiology - clinical.
©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.